- Home
- GLDG vs PBYI Comparison
GLDG vs PBYI Comparison
Compare GLDG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDG
- PBYI
- Stock Information
- Founded
- GLDG 2009
- PBYI 2010
- Country
- GLDG Canada
- PBYI United States
- Employees
- GLDG N/A
- PBYI N/A
- Industry
- GLDG Precious Metals
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GLDG Basic Materials
- PBYI Health Care
- Exchange
- GLDG Nasdaq
- PBYI Nasdaq
- Market Cap
- GLDG 157.0M
- PBYI 138.4M
- IPO Year
- GLDG N/A
- PBYI N/A
- Fundamental
- Price
- GLDG $0.79
- PBYI $3.07
- Analyst Decision
- GLDG Strong Buy
- PBYI Strong Buy
- Analyst Count
- GLDG 1
- PBYI 1
- Target Price
- GLDG $3.25
- PBYI $7.00
- AVG Volume (30 Days)
- GLDG 537.0K
- PBYI 275.3K
- Earning Date
- GLDG 04-11-2025
- PBYI 05-08-2025
- Dividend Yield
- GLDG N/A
- PBYI N/A
- EPS Growth
- GLDG N/A
- PBYI 37.78
- EPS
- GLDG N/A
- PBYI 0.62
- Revenue
- GLDG N/A
- PBYI $230,468,000.00
- Revenue This Year
- GLDG N/A
- PBYI N/A
- Revenue Next Year
- GLDG N/A
- PBYI N/A
- P/E Ratio
- GLDG N/A
- PBYI $4.92
- Revenue Growth
- GLDG N/A
- PBYI N/A
- 52 Week Low
- GLDG $0.71
- PBYI $2.23
- 52 Week High
- GLDG $1.06
- PBYI $5.20
- Technical
- Relative Strength Index (RSI)
- GLDG 48.64
- PBYI 51.76
- Support Level
- GLDG $0.75
- PBYI $2.88
- Resistance Level
- GLDG $0.79
- PBYI $3.14
- Average True Range (ATR)
- GLDG 0.03
- PBYI 0.14
- MACD
- GLDG 0.00
- PBYI 0.01
- Stochastic Oscillator
- GLDG 44.50
- PBYI 64.00
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia, Crucero project, located in Peru, Sao Jorge, Batistao, Boa Vista, located in Brazil, Yellowknife Gold Project, located in the Northwest Territories, Canada, and other projects. The company earns maximum revenue from Canada.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.